Inflammatory carcinoma of the breast. A therapeutic approach followed by improved survival.
Disappointing results of radical mastectomy for treatment of inflammatory breast carcinoma led to its abandonment and the use of alternative therapeutic methods without improvement of survival rates. Results of radical mastectomy combined with other therapeutic modalities have not been fully evaluated so far. In a series of nine patients with proven inflammatory breast carcinoma and no distant metastases, two underwent radiotherapy, oophorectomy, and adrenalectomy (group A) and seven underwent preoperative irradiation, radical mastectomy, postoperative irradiation, and chemotherapy (group B). There were no local recurrences in either group. Group A patients survived five and eight months (mean, 6.6+/-2.1) and patients of group B survived 45.5+/-26.2 months (p less than 0.05). Results show no rational basis for withholding radical mastectomy, but suggest that improved survival may be obtained when radical mastectomy is an integral part of a rational sequential therapeutic schedule.
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D002369:Castration; D005260:Female; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000532:radiotherapy; D013852:Thiotepa / Q000627:therapeutic use*
D013852:Thiotepa